 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
|
|
| |
| Company Profile |
| |
|
ArQule, Inc., a biotechnology company, engages in the research and development of small-molecule cancer therapeutics based on its Activated Checkpoint Therapy (ACT) platform. The ACT platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. Its primary product consists of ARQ 501, a Phase I oncology product for cancer patients with solid tumors. The company also has products in preclinical and research stages. It also provides chemistry services to pharmaceutical and biotechnology companies to produce novel chemical compounds with drug-like characteristics. ArQule was founded in 1993 and is headquartered in Woburn, Massachusetts.
|
ARQULE INC Related |
|
ArQule Promotes their activated checkpoint therapy platform. Headquartered in Woburn, Massachusetts. ... 10/27/08 ArQule, Inc. to Present at Upcoming Investor Conferences ...
|
|
ArQule Inc: Information from Answers.com ArQule, Inc. (NASDAQ (GM):ARQL) Company Financials Income Statement Balance Sheet Cash Flow Statement Contact Information ArQule, Inc
|
|
ARQL: Summary for ArQule, Inc. - Yahoo! Finance ... information on ArQule, Inc. ... ARQULE INC Files SEC form 8-K, Results of Operations and ... ArQule, Inc. Earnings Call scheduled for 9:00 am ET today ...
|
|
|
|
|
